S&P Global Inc vs Tempus AI — how do they compare? S&P Global Inc trades at $403.72 (market cap $116.50B), while Tempus AI trades at $70.59 (market cap $12.77B). The key difference: S&P Global Inc is far larger — about 9.1× Tempus AI's market cap, and S&P Global Inc pays a 0.98% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 123 Days and Tempus AI for 22 Days on average.
| SPGI | TEM | |
|---|---|---|
Market Cap | $116.50B | $12.77B |
Volume | 1,430,714 | 8,980,490 |
Sector | Financials | Broad Market / Factor |
52-Week High | $517.92 | $99.28 |
52-Week Low | $370.42 | $41.55 |
Typical Hold Time | 123 Days | 22 Days |
Enterprise Value | $127.99B | $13.40B |
Dividend Yield | 0.98% | — |
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $402.73, up 1.67% with strong analyst support showing 85.7% buy ratings and a $509.50 consensus price target. The stock faces technical headwinds with bearish moving averages but maintains robust fundamentals including 30.5% net margins and consistent revenue growth from $15.3B to $16.1B projected for 2026. Recent developments include expansion into digital asset risk assessment and the acquisition of OpenZeppelin, positioning the company for AI-driven growth across its financial services divisions.
The outlook remains positive given S&P Global's dominant market position and margin expansion potential, though investors should monitor debt levels increasing to 23.3% of assets. Near-term catalysts include Q3 2026 earnings on October 27, with the stock offering 26% upside to analyst targets despite current technical weakness suggesting potential entry points near $391 support.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →